NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...
Novo Nordisk's future growth potential is further bolstered by its robust pipeline of innovative treatments. The company is developing next-generation assets like CagriSema, which aims to improve ...
Novo Nordisk Reports Strong Q4 Revenue and Profit ... the details about its upcoming weight loss and diabetes treatment, Cagrisema. The injectable showed just barely higher placebo-adjusted ...
Novo Nordisk's phase 3 CagriSema study on obesity, named "REDEFINE-1." Defendants' statements failed to disclose or otherwise misled investors as to the nature of the dosages provided to patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results